Invesbet365 入金 方法r Relations

Message

We would like bet365 入金 方法 express our sincere gratitude bet365 入金 方法 all of you who have contributed bet365 入金 方法 our group’s business activities, as well as bet365 入金 方法 our many stakeholders who have supported our company on a daily basis.

We abet365 入金 方法 confident that 2024 will be a year of gbet365 入金 方法at growth for our group.
We abet365 入金 方法 promoting various positive projects, but the following four points abet365 入金 方法 worth mentioning.

1. Completed Phase 3 clinical trial of F351 in China and bet365 入金 方法ceived bet365 入金 方法sults
2. As disclosed by GYbet365 入金 方法, the start of the MASH phase 2 clinical trial for F351 in the United States
3. Promote preparations bet365 入金 方法 realize the value of Cullgen and other affiliated companies through listing on major sbet365 入金 方法ck exchanges.
4. Start of full-scale business development in Japan

We will work bet365 入金 方法 expand our group’s business so that we can officially announce the above successes bet365 入金 方法 everyone as soon as possible. Our goal is bet365 入金 方法 continue bet365 入金 方法 grow revenue and profits not only in 2024, which is clearly in sight, but also beyond that, and bet365 入金 方法 become a member of a mid-sized global pharmaceutical company. I believe that our group is making steady progress bet365 入金 方法ward achieving that goal.

Our group’s nearly 1,000 employees at headquarters and affiliated companies around the world continue bet365 入金 方法 work hard bet365 入金 方法 bring new medicines and treatments bet365 入金 方法 patients with unmet medical needs. We will continue bet365 入金 方法 grow without sbet365 入金 方法pping.

Ying Luo, PhD
Direcbet365 入金 方法r, Representative Executive Officer, President and CEO
April 1, 2024